Information

Related Research Units

Dana Farber Boston Childrens Cancer and Blood Disorders Center Research
Hematology and Oncology Research

Research Overview

Dr. London has three primary research interests: neuroblastoma, prognostic stratification, and design of clinical trials. Her findings on the effect of age on neuroblastoma outcome resulted in a reduction of therapy for patients 12-18 months old. In the consensus efforts of the International Neuroblastoma Risk Group (INRG), she is the chair the Statistics Committee. Dr. London and her committee assembled the largest neuroblastoma database in the world (n=11,500). For prognostic stratification of this database, she performed survival tree regression, whereby 16 pre-treatment groups were determined, each statistically and/or clinically unique, accepted worldwide as building blocks for future trials. In this project, Dr. London eliminated the redundancy of histopathologic classification and age in risk stratification. As the Lead Statistician for the Neuroblastoma Committee of the Children?s Oncology Group, Dr. London's collaborative neuroblastoma research includes: a) therapy reduction for low-risk and intermediate-risk neuroblastoma; b) demonstrating no role for purging in high-risk neuroblastoma; and, c) demonstrating a 20% improvement in 2-year event-free survival for high-risk neuroblastoma patients treated post-transplant with cytokines and chimeric 14.18 antibody (immunotherapy). Dr. London has performed statistical methodological research in the design of clinical trials. She developed new methods for stratified Phase II designs, now widely used in multi-center trials for small, heterogeneous cohorts. Dr. London performed a novel application of casual inference methodology in a Phase II trial in order to improve the ability to interpret long-term outcome despite confounding by off-protocol therapy.

 

Research Background

Dr. London received a PhD in Biostatistics from Virginia Commonwealth University, She is a member of the American Statistical Association, International Society for Pediatric Oncology, and American Society for Clinical Oncology. In 2006, Dr. London received the Audrey Evans Prize for Outstanding Paper in Clinical Research, Advances in Neuroblastoma Research Association.

At BCH and DFCHCC, Dr. London directs approximately 30 members of the CTIP staff, and 3 members of the Biostatistics Program in the conduct of collaborative research and to provide infrastructure for the operations of the Division.

Publications

  1. Targeted-Agent Continual Reassessment Method: A Novel Bayesian Enrichment Design for Phase I Trials of Molecularly Targeted Therapies. JCO Precis Oncol. 2024 Dec; 8:e2400360. View Abstract
  2. A comparative analysis of IDH-mutant glioma in pediatric, young adult, and older adult patients. Neuro Oncol. 2024 Dec 05; 26(12):2364-2376. View Abstract
  3. Statistical Fragility of Findings From Randomized Phase 3 Trials in Pediatric Oncology. Cancer Med. 2024 Dec; 13(24):e70356. View Abstract
  4. Outcomes of patients with intermediate-risk neuroblastoma presenting with motor deficits relating to intraspinal tumor extension: A report from the Children's Oncology Group study ANBL0531. Pediatr Blood Cancer. 2025 Jan; 72(1):e31407. View Abstract
  5. Improvements in Children's Oncology Group neuroblastoma risk stratification through a change in age cut-off and use of INRGSS. Transl Pediatr. 2024 Oct 01; 13(10):1899-1901. View Abstract
  6. Trends in the Diagnosis of Pediatric Venous Thromboembolism and Arterial Ischemic Stroke during the COVID-19 Pandemic: An Administrative Database Study. J Pediatr. 2025 Jan; 276:114328. View Abstract
  7. Evaluation of Image-Defined Risk Factor (IDRF) Assessment in Patients With Intermediate-risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. J Pediatr Surg. 2025 Jan; 60(1):161896. View Abstract
  8. Author Correction: Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer. Nat Commun. 2024 Aug 22; 15(1):7218. View Abstract
  9. Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer. Nat Commun. 2024 Jul 11; 15(1):5837. View Abstract
  10. Long-term follow-up of patients with intermediate-risk neuroblastoma treated with response- and biology-based therapy: A report from the Children's Oncology Group study ANBL0531. Pediatr Blood Cancer. 2024 Aug; 71(8):e31089. View Abstract
  11. Pediatric transplant-associated thrombotic microangiopathy health care utilization and implications of eculizumab therapy. Blood Adv. 2024 03 12; 8(5):1220-1233. View Abstract
  12. A Pilot Study Omitting Radiation in the Treatment of Children with Newly Diagnosed Wnt-Activated Medulloblastoma. Clin Cancer Res. 2023 12 15; 29(24):5031-5037. View Abstract
  13. Risk factors and outcomes of melanoma in children and adolescents: A retrospective multicenter study. J Am Acad Dermatol. 2024 Apr; 90(4):716-726. View Abstract
  14. Monte Carlo based dosimetry of extraoral photobiomodulation for prevention of oral mucositis. Sci Rep. 2023 11 22; 13(1):20425. View Abstract
  15. Outcomes of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome. Blood. 2023 10 12; 142(15):1281-1296. View Abstract
  16. Phase 1 study of cabozantinib in combination with topotecan-cyclophosphamide for patients with relapsed Ewing sarcoma or osteosarcoma. Pediatr Blood Cancer. 2023 Dec; 70(12):e30681. View Abstract
  17. Correlation between Multiparametric MR Imaging and Molecular Genetics in Pontine Pediatric High-Grade Glioma. AJNR Am J Neuroradiol. 2023 07; 44(7):833-840. View Abstract
  18. Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma. Cancer Med. 2023 07; 12(14):15207-15216. View Abstract
  19. A single-institution pediatric and young adult interventional oncology collaborative: Novel therapeutic options for relapsed/refractory solid tumors. Cancer Med. 2023 06; 12(12):13300-13308. View Abstract
  20. Impact of diagnostic and end-of-induction Curie scores with tandem high-dose chemotherapy and autologous transplants for metastatic high-risk neuroblastoma: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2023 Aug; 70(8):e30418. View Abstract
  21. Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk Stratification. J Clin Oncol. 2023 06 10; 41(17):3149-3159. View Abstract
  22. KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children's Oncology Group. J Immunother Cancer. 2023 02; 11(2). View Abstract
  23. Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease. J Clin Oncol. 2023 04 20; 41(12):2227-2237. View Abstract
  24. WANTED: Better neuroblastoma biomarkers and better stratification. EBioMedicine. 2022 12; 86:104358. View Abstract
  25. Clinical and biological features prognostic of survival after relapse or progression of INRGSS stage MS pattern neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2023 02; 70(2):e30054. View Abstract
  26. Direct capture of neutralized RBD enables rapid point-of-care assessment of SARS-CoV-2 neutralizing antibody titer. Cell Rep Methods. 2022 08 22; 2(8):100273. View Abstract
  27. Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group. J Clin Oncol. 2022 12 10; 40(35):4107-4118. View Abstract
  28. Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nat Med. 2022 08; 28(8):1581-1589. View Abstract
  29. Microbiota dynamics in a randomized trial of gut decontamination during allogeneic hematopoietic cell transplantation. JCI Insight. 2022 04 08; 7(7). View Abstract
  30. Health Literacy and Clinical Outcomes Following Hematopoietic Stem-Cell Transplantation. JCO Oncol Pract. 2022 06; 18(6):e857-e868. View Abstract
  31. Validation of a Monte Carlo Modelling Based Dosimetry of Extraoral Photobiomodulation. Diagnostics (Basel). 2021 Nov 26; 11(12). View Abstract
  32. Prevalence and Predictors of Iron Deficiency in Adolescent and Young Adult Outpatients: Implications for Screening. Clin Pediatr (Phila). 2022 01; 61(1):66-75. View Abstract
  33. Phase 3 randomised trial of eltrombopag versus standard first-line pharmacological management for newly diagnosed immune thrombocytopaenia (ITP) in children: study protocol. BMJ Open. 2021 08 27; 11(8):e044885. View Abstract
  34. Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors. Pediatr Blood Cancer. 2021 11; 68(11):e29282. View Abstract
  35. Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology Group. Am J Surg Pathol. 2021 08 01; 45(8):1075-1081. View Abstract
  36. Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. J Clin Oncol. 2021 10 10; 39(29):3229-3241. View Abstract
  37. The Path to an Evidence-Based Treatment Protocol for Extraoral Photobiomodulation Therapy for the Prevention of Oral Mucositis. Front Oral Health. 2021; 2:689386. View Abstract
  38. Association Between Participation in Clinical Trials and Overall Survival Among Children With Intermediate- or High-risk Neuroblastoma. JAMA Netw Open. 2021 07 01; 4(7):e2116248. View Abstract
  39. Pyruvate kinase deficiency in children. Pediatr Blood Cancer. 2021 09; 68(9):e29148. View Abstract
  40. A G316A Polymorphism in the Ornithine Decarboxylase Gene Promoter Modulates MYCN-Driven Childhood Neuroblastoma. Cancers (Basel). 2021 Apr 09; 13(8). View Abstract
  41. Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1. Transplant Cell Ther. 2021 06; 27(6):490.e1-490.e8. View Abstract
  42. Building a Harmonized Datamart by Integrating Cross-Institutional Systems of Clinical, Outcome, and Genomic Data: The Pediatric Patient Informatics Platform (PPIP). JCO Clin Cancer Inform. 2021 02; 5:202-215. View Abstract
  43. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clin Cancer Res. 2021 04 15; 27(8):2179-2189. View Abstract
  44. Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease. N Engl J Med. 2021 01 21; 384(3):205-215. View Abstract
  45. A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2021 03; 68(3):e28794. View Abstract
  46. A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma. Pediatr Blood Cancer. 2021 02; 68(2):e28787. View Abstract
  47. Ganglioneuromas are driven by activated AKT and can be therapeutically targeted with mTOR inhibitors. J Exp Med. 2020 10 05; 217(10). View Abstract
  48. Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future. JCO Clin Cancer Inform. 2020 10; 4:895-905. View Abstract
  49. Reply to K. Beiske et al. J Clin Oncol. 2020 11 01; 38(31):3720-3721. View Abstract
  50. Race Disparities in Proton Radiotherapy Use for Cancer Treatment in Patients Enrolled in Children's Oncology Group Trials. JAMA Oncol. 2020 09 01; 6(9):1465-1468. View Abstract
  51. Race Disparities in Proton Radiotherapy Use for Cancer Treatment in Patients Enrolled in Children's Oncology Group Trials. JAMA Oncol. 2020 Aug 06. View Abstract
  52. Characterization of the severe phenotype of pyruvate kinase deficiency. Am J Hematol. 2020 Oct; 95(10):E281-E285. View Abstract
  53. Characteristics of nonmelanoma skin cancer in children without identifiable risk factors. J Am Acad Dermatol. 2021 May; 84(5):1472-1476. View Abstract
  54. A retrospective multicenter study of fatal pediatric melanoma. J Am Acad Dermatol. 2020 Nov; 83(5):1274-1281. View Abstract
  55. Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Children's Oncology Group ANBL0532 Study. J Clin Oncol. 2020 08 20; 38(24):2741-2752. View Abstract
  56. The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2020 08; 67(8):e28359. View Abstract
  57. The pyruvate kinase (PK) to hexokinase enzyme activity ratio and erythrocyte PK protein level in the diagnosis and phenotype of PK deficiency. Br J Haematol. 2021 03; 192(6):1092-1096. View Abstract
  58. Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group. J Clin Oncol. 2020 07 01; 38(19):2160-2169. View Abstract
  59. Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project. J Clin Oncol. 2020 06 10; 38(17):1906-1918. View Abstract
  60. Genotype-phenotype correlation and molecular heterogeneity in pyruvate kinase deficiency. Am J Hematol. 2020 05; 95(5):472-482. View Abstract
  61. Comparison of Outcomes of Myeloablative Allogeneic Stem Cell Transplantation for Pediatric Patients with Bone Marrow Failure, Myelodysplastic Syndrome and Acute Myeloid Leukemia with and without Germline GATA2 Mutations. Biol Blood Marrow Transplant. 2020 06; 26(6):1124-1130. View Abstract
  62. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. JAMA. 2019 08 27; 322(8):746-755. View Abstract
  63. Sun exposure and protection practices in children after allogeneic hematopoietic stem cell transplantation: A Survey-Based Cross-Sectional Cohort Study. Pediatr Dermatol. 2019 Nov; 36(6):882-886. View Abstract
  64. Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. J Clin Oncol. 2019 12 01; 37(34):3243-3255. View Abstract
  65. Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study. Clin Cancer Res. 2019 10 15; 25(20):6044-6051. View Abstract
  66. Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2019 08; 66(8):e27819. View Abstract
  67. Risk Factors and Outcomes of Nonmelanoma Skin Cancer in Children and Young Adults. J Pediatr. 2019 08; 211:152-158. View Abstract
  68. Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study. Pediatr Blood Cancer. 2019 07; 66(7):e27736. View Abstract
  69. Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG). Eur J Cancer. 2019 05; 112:66-79. View Abstract
  70. Correction: Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. Br J Cancer. 2019 Apr; 120(8):869. View Abstract
  71. Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma. Sci Transl Med. 2019 01 30; 11(477). View Abstract
  72. Statistical Framework in Support of a Revised Children's Oncology Group Neuroblastoma Risk Classification System. JCO Clin Cancer Inform. 2018 12; 2:1-15. View Abstract
  73. The challenge of defining "ultra-high-risk" neuroblastoma. Pediatr Blood Cancer. 2019 04; 66(4):e27556. View Abstract
  74. Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531. J Clin Oncol. 2019 01 10; 37(2):115-124. View Abstract
  75. Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients. Blood Adv. 2018 10 09; 2(19):2505-2512. View Abstract
  76. Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients. J Natl Cancer Inst. 2018 10 01; 110(10):1084-1093. View Abstract
  77. Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study. Haematologica. 2019 02; 104(2):e51-e53. View Abstract
  78. Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. Br J Cancer. 2018 08; 119(5):615-621. View Abstract
  79. Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931. Front Immunol. 2018; 9:1641. View Abstract
  80. A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931. Front Immunol. 2018; 9:1355. View Abstract
  81. Normalizing hepcidin predicts TMPRSS6 mutation status in patients with chronic iron deficiency. Blood. 2018 07 26; 132(4):448-452. View Abstract
  82. The Effectiveness of a Hospital-Based School Liaison Program: A Comparative Study of Parental Perception of School Supports for Children With Pediatric Cancer and Neurofibromatosis Type 1. J Pediatr Oncol Nurs. 2018 Jul/Aug; 35(4):276-286. View Abstract
  83. Nonmalignant late cutaneous changes after allogeneic hematopoietic stem cell transplant in children. J Am Acad Dermatol. 2018 Aug; 79(2):230-237. View Abstract
  84. Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study. Blood. 2018 05 17; 131(20):2183-2192. View Abstract
  85. Response Evaluation Criteria in Solid Tumors (RECIST) following neoadjuvant chemotherapy in osteosarcoma. Pediatr Blood Cancer. 2018 04; 65(4). View Abstract
  86. MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group. Oncotarget. 2018 Jan 19; 9(5):6416-6432. View Abstract
  87. Provider Perspectives on Use of Medical Marijuana in Children With Cancer. Pediatrics. 2018 01; 141(1). View Abstract
  88. Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. Lancet Child Adolesc Health. 2018 01; 2(1):25-34. View Abstract
  89. Screening with whole-body magnetic resonance imaging in pediatric subjects with Li-Fraumeni syndrome: A single institution pilot study. Pediatr Blood Cancer. 2018 Feb; 65(2). View Abstract
  90. Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group. Clin Cancer Res. 2018 01 01; 24(1):189-196. View Abstract
  91. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials. Cancer. 2017 Dec 15; 123(24):4914-4923. View Abstract
  92. Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival. J Neurooncol. 2017 Oct; 135(1):201-211. View Abstract
  93. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. Cancer. 2017 Nov 01; 123(21):4224-4235. View Abstract
  94. HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy. Front Immunol. 2017; 8:675. View Abstract
  95. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Lancet Oncol. 2017 07; 18(7):946-957. View Abstract
  96. Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2017 Aug 01; 35(22):2580-2587. View Abstract
  97. Reply to J. Stenman et al. J Clin Oncol. 2017 06 10; 35(17):1966-1967. View Abstract
  98. Risk of melanocytic nevi and nonmelanoma skin cancer in children after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2017 Jul; 52(7):989-997. View Abstract
  99. Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project. Eur J Cancer. 2017 02; 72:177-185. View Abstract
  100. A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers. Cancer Res. 2017 02 15; 77(4):971-981. View Abstract
  101. Impact of Extent of Resection on Local Control and Survival in Patients From the COG A3973 Study With High-Risk Neuroblastoma. J Clin Oncol. 2017 Jan 10; 35(2):208-216. View Abstract
  102. Patterns of Relapse in High-Risk Neuroblastoma Patients Treated With and Without Total Body Irradiation. Int J Radiat Oncol Biol Phys. 2017 02 01; 97(2):270-277. View Abstract
  103. MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4. Oncotarget. 2016 Aug 23; 7(34):54937-54951. View Abstract
  104. Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma. PLoS One. 2016; 11(8):e0161039. View Abstract
  105. Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database. Eur J Cancer. 2016 09; 65:1-10. View Abstract
  106. Cytomegalovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation: Risk Factors for Primary Infection and Cases of Recurrent and Late Infection at a Single Center. Biol Blood Marrow Transplant. 2016 07; 22(7):1275-1283. View Abstract
  107. Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. JAMA Oncol. 2016 May 01; 2(5):608-615. View Abstract
  108. MYC-Driven Neuroblastomas Are Addicted to a Telomerase-Independent Function of Dyskerin. Cancer Res. 2016 06 15; 76(12):3604-17. View Abstract
  109. A Feasibility Study Evaluating Extraoral Photobiomodulation Therapy for Prevention of Mucositis in Pediatric Hematopoietic Cell Transplantation. Photomed Laser Surg. 2016 Apr; 34(4):178-84. View Abstract
  110. End-of-Life Care Patterns Associated with Pediatric Palliative Care among Children Who Underwent Hematopoietic Stem Cell Transplant. Biol Blood Marrow Transplant. 2016 06; 22(6):1049-1055. View Abstract
  111. Newborn Screening for Sickle Cell Disease in Liberia: A Pilot Study. Pediatr Blood Cancer. 2016 Apr; 63(4):671-6. View Abstract
  112. Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project. Cancer. 2016 Mar 15; 122(6):935-45. View Abstract
  113. Use and Effectiveness of Gonadotropin-Releasing Hormone Agonists for Prophylactic Menstrual Suppression in Postmenarchal Women Who Undergo Hematopoietic Cell Transplantation. J Pediatr Adolesc Gynecol. 2016 Jun; 29(3):265-8. View Abstract
  114. Trajectory of Material Hardship and Income Poverty in Families of Children Undergoing Chemotherapy: A Prospective Cohort Study. Pediatr Blood Cancer. 2016 Jan; 63(1):105-11. View Abstract
  115. Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol. 2015 Sep 20; 33(27):3008-17. View Abstract
  116. Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism. Oncotarget. 2015 Jul 30; 6(21):18558-76. View Abstract
  117. Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study. Br J Cancer. 2015 Jun 30; 113(1):57-63. View Abstract
  118. SIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and middle-income settings. Pediatr Blood Cancer. 2015 Aug; 62(8):1305-16. View Abstract
  119. Pediatric aplastic anemia and refractory cytopenia: A retrospective analysis assessing outcomes and histomorphologic predictors. Am J Hematol. 2015 Apr; 90(4):320-6. View Abstract
  120. Incidence and causes of hospital readmission in pediatric patients after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015 May; 21(5):913-9. View Abstract
  121. Voriconazole phototoxicity in children: a retrospective review. J Am Acad Dermatol. 2015 Feb; 72(2):314-20. View Abstract
  122. Reply to N.-K.V. Cheung et al. J Clin Oncol. 2014 Dec 20; 32(36):4174-5. View Abstract
  123. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell. 2014 Nov 10; 26(5):682-94. View Abstract
  124. Prevalence and impact of financial hardship among New England pediatric stem cell transplantation families. Biol Blood Marrow Transplant. 2015 Feb; 21(2):312-8. View Abstract
  125. Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a children's oncology group report. Pediatr Blood Cancer. 2015 Jan; 62(1):60-4. View Abstract
  126. A modified ?-retrovirus vector for X-linked severe combined immunodeficiency. N Engl J Med. 2014 Oct 09; 371(15):1407-17. View Abstract
  127. Age-dependent prognostic effect by Mitosis-Karyorrhexis Index in neuroblastoma: a report from the Children's Oncology Group. Pediatr Dev Pathol. 2014 Nov-Dec; 17(6):441-9. View Abstract
  128. Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project. J Clin Oncol. 2014 Oct 01; 32(28):3169-76. View Abstract
  129. Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2014 Nov; 61(11):1932-9. View Abstract
  130. Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1. Oncotarget. 2014 Jun 30; 5(12):4257-68. View Abstract
  131. Balancing education and service in graduate medical education: data from pediatric trainees and program directors. Acad Med. 2014 Apr; 89(4):652-7. View Abstract
  132. Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: A study from the International Neuroblastoma Risk Group Database. J Clin Oncol. 2014 Apr 20; 32(12):1228-35. View Abstract
  133. Integrating cell-based and clinical genome-wide studies to identify genetic variants contributing to treatment failure in neuroblastoma patients. Clin Pharmacol Ther. 2014 Jun; 95(6):644-52. View Abstract
  134. Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounter™ system. Mol Oncol. 2014 May; 8(3):669-78. View Abstract
  135. Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database. Pediatr Blood Cancer. 2014 Jul; 61(7):1173-9. View Abstract
  136. Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology Group. J Clin Oncol. 2014 Feb 20; 32(6):527-34. View Abstract
  137. Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621). Pediatr Blood Cancer. 2014 Jun; 61(6):990-6. View Abstract
  138. Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2014 Apr; 61(4):627-35. View Abstract
  139. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group. Cancer. 2013 Oct 15; 119(20):3718-26. View Abstract
  140. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol. 2013 Sep; 14(10):999-1008. View Abstract
  141. Predictors of neoplastic disease in children with isolated pituitary stalk thickening. Pediatr Blood Cancer. 2013 Oct; 60(10):1630-5. View Abstract
  142. Development of an open-source, flexible framework for complex inter-institutional disparate data sharing and collaboration. AMIA Jt Summits Transl Sci Proc. 2013; 2013:103. View Abstract
  143. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group. J Nucl Med. 2013 Apr; 54(4):541-8. View Abstract
  144. A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1. Bone Marrow Transplant. 2013 Jul; 48(7):947-52. View Abstract
  145. The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013 Mar; 45(3):279-84. View Abstract
  146. Children's Oncology Group's 2013 blueprint for research: neuroblastoma. Pediatr Blood Cancer. 2013 Jun; 60(6):985-93. View Abstract
  147. Trans-population analysis of genetic mechanisms of ethnic disparities in neuroblastoma survival. J Natl Cancer Inst. 2013 Feb 20; 105(4):302-9. View Abstract
  148. Effect of weight on outcomes of children undergoing hematopoietic cell transplantation. Pediatr Hematol Oncol. 2013 Mar; 30(2):116-30. View Abstract
  149. A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study. Ann Surg. 2012 Oct; 256(4):573-80. View Abstract
  150. Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group. Int J Mol Imaging. 2012; 2012:250834. View Abstract
  151. Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project. Br J Cancer. 2012 Oct 09; 107(8):1418-22. View Abstract
  152. Pediatric sarcoma in Central America: outcomes, challenges, and plans for improvement. Cancer. 2013 Feb 15; 119(4):871-9. View Abstract
  153. Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J Clin Oncol. 2012 Oct 01; 30(28):3525-32. View Abstract
  154. Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2012 Dec 15; 59(7):1259-65. View Abstract
  155. Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer Res. 2012 Oct 15; 18(20):5773-9. View Abstract
  156. Feasibility of a tandem autologous peripheral blood stem cell transplant regimen for high risk neuroblastoma in a cooperative group setting: a Pediatric Oncology Group study: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2012 Nov; 59(5):902-7. View Abstract
  157. Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee. Pediatr Blood Cancer. 2013 Mar; 60(3):363-70. View Abstract
  158. Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641. J Clin Oncol. 2012 May 20; 30(15):1842-8. View Abstract
  159. Sleep dysfunction in long term survivors of craniopharyngioma. J Neurooncol. 2012 Jul; 108(3):543-9. View Abstract
  160. Overcoming reprogramming resistance of Fanconi anemia cells. Blood. 2012 Jun 07; 119(23):5449-57. View Abstract
  161. Mechanisms of CHD5 Inactivation in neuroblastomas. Clin Cancer Res. 2012 Mar 15; 18(6):1588-97. View Abstract
  162. N-Myc regulates expression of the detoxifying enzyme glutathione transferase GSTP1, a marker of poor outcome in neuroblastoma. Cancer Res. 2012 Feb 15; 72(4):845-53. View Abstract
  163. Tumor histology during induction therapy in patients with high-risk neuroblastoma. Pediatr Blood Cancer. 2012 Sep; 59(3):506-10. View Abstract
  164. Characteristics and outcome of patients with ganglioneuroblastoma, nodular subtype: a report from the INRG project. Eur J Cancer. 2012 May; 48(8):1185-91. View Abstract
  165. miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples. Clin Cancer Res. 2011 Dec 15; 17(24):7684-92. View Abstract
  166. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2011 Nov 20; 29(33):4351-7. View Abstract
  167. Clinical significance of NTRK family gene expression in neuroblastomas. Pediatr Blood Cancer. 2012 Aug; 59(2):226-32. View Abstract
  168. Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age. J Clin Oncol. 2011 Nov 20; 29(33):4358-64. View Abstract
  169. Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group. Clin Cancer Res. 2011 Nov 01; 17(21):6858-66. View Abstract
  170. ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux. J Natl Cancer Inst. 2011 Aug 17; 103(16):1236-51. View Abstract
  171. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol. 2011 Aug 20; 29(24):3286-92. View Abstract
  172. Ototoxicity in children with high-risk neuroblastoma: Prevalence, risk factors, and concordance of grading scales-A report from the Children's Oncology Group (COG). J Clin Oncol. 2011 May 20; 29(15_suppl):9515. View Abstract
  173. Stratification of patients with neuroblastoma for targeted ALK inhibitor therapy. J Clin Oncol. 2011 May 20; 29(15_suppl):9514. View Abstract
  174. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology. 2011 Oct; 261(1):243-57. View Abstract
  175. Comparison of ¹²³I-metaiodobenzylguanidine (MIBG) and ¹³¹I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2011 Jul 01; 56(7):1041-5. View Abstract
  176. CASZ1, a candidate tumor-suppressor gene, suppresses neuroblastoma tumor growth through reprogramming gene expression. Cell Death Differ. 2011 Jul; 18(7):1174-83. View Abstract
  177. Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature. 2011 Jan 13; 469(7329):216-20. View Abstract
  178. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2011 Jan 10; 29(2):208-13. View Abstract
  179. Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project. Eur J Cancer. 2011 Mar; 47(4):561-71. View Abstract
  180. Racial and ethnic disparities in risk and survival in children with neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2011 Jan 01; 29(1):76-82. View Abstract
  181. Genotypes of NK cell KIR receptors, their ligands, and Fc? receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res. 2010 Dec 01; 70(23):9554-61. View Abstract
  182. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol. 2010 Nov 20; 28(33):4969-75. View Abstract
  183. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med. 2010 Sep 30; 363(14):1313-23. View Abstract
  184. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010 Sep 30; 363(14):1324-34. View Abstract
  185. microRNA signature and expression of Dicer and Drosha can predict prognosis and delineate risk groups in neuroblastoma. Cancer Res. 2010 Oct 15; 70(20):7841-50. View Abstract
  186. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2010 Aug 20; 28(24):3808-15. View Abstract
  187. Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology Group. Pediatr Blood Cancer. 2010 Apr; 54(4):596-602. View Abstract
  188. The use of central laboratories and remote electronic data capture to risk-adjust therapy for pediatric acute lymphoblastic leukemia and neuroblastoma. Semin Oncol. 2010 Feb; 37(1):53-9. View Abstract
  189. Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group. Cancer. 2009 Dec 15; 115(24):5828-35. View Abstract
  190. Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival. PLoS One. 2009 Nov 16; 4(11):e7850. View Abstract
  191. Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG. Pediatr Blood Cancer. 2009 Oct; 53(4):563-9. View Abstract
  192. Influence of neuroblastoma stage on serum-based detection of MYCN amplification. Pediatr Blood Cancer. 2009 Sep; 53(3):329-31. View Abstract
  193. Prognostic significance of interleukin-6 single nucleotide polymorphism genotypes in neuroblastoma: rs1800795 (promoter) and rs8192284 (receptor). Clin Cancer Res. 2009 Aug 15; 15(16):5234-9. View Abstract
  194. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood. 2009 Sep 03; 114(10):2051-9. View Abstract
  195. Copy number variation at 1q21.1 associated with neuroblastoma. Nature. 2009 Jun 18; 459(7249):987-91. View Abstract
  196. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol. 2009 Jul; 10(7):663-71. View Abstract
  197. Significance of tumor biology compared to metastatic pattern (INSS 4 versus 4s) and age for prognosis of neuroblastoma less than 18 months of age. J Clin Oncol. 2009 May 20; 27(15_suppl):10010. View Abstract
  198. Irinotecan plus temozolomide in children with recurrent or refractory neuroblastoma: A phase II Children's Oncology Group study. J Clin Oncol. 2009 May 20; 27(15_suppl):10011. View Abstract
  199. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer. 2009 May 05; 100(9):1471-82. View Abstract
  200. Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet. 2009 Jun; 41(6):718-23. View Abstract
  201. A finite mixture survival model to characterize risk groups of neuroblastoma. Stat Med. 2009 Apr 15; 28(8):1301-14. View Abstract
  202. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol. 2009 Mar 01; 27(7):1007-13. View Abstract
  203. Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2009 Jan; 52(1):44-50. View Abstract
  204. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Cancer Res. 2008 Dec 01; 68(23):9735-45. View Abstract
  205. Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database. J Clin Oncol. 2009 Jan 20; 27(3):365-70. View Abstract
  206. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2009 Jan 10; 27(2):298-303. View Abstract
  207. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2009 Jan 10; 27(2):289-97. View Abstract
  208. Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2008 Dec; 51(6):747-53. View Abstract
  209. Lung metastases in neuroblastoma at initial diagnosis: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2008 Nov; 51(5):589-92. View Abstract
  210. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008 Oct 16; 455(7215):975-8. View Abstract
  211. CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J Natl Cancer Inst. 2008 Jul 02; 100(13):940-9. View Abstract
  212. Focal adhesion kinase expression in human neuroblastoma: immunohistochemical and real-time PCR analyses. Clin Cancer Res. 2008 Jun 01; 14(11):3299-305. View Abstract
  213. Prognostic markers for stage 3 neuroblastoma (NB): A report from the International Neuroblastoma Risk Group (INRG) project. J Clin Oncol. 2008 May 20; 26(15_suppl):10009. View Abstract
  214. A randomized phase III trial of myeloablative autologous peripheral blood stem cell (PBSC) transplant (ASCT) for high-risk neuroblastoma (HR-NB) employing immunomagnetic purged (P) versus unpurged (UP) PBSC: A Children's Oncology Group study. J Clin Oncol. 2008 May 20; 26(15_suppl):10011. View Abstract
  215. Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med. 2008 Jun 12; 358(24):2585-93. View Abstract
  216. Application of the adult international germ cell classification system to pediatric malignant non-seminomatous germ cell tumors: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2008 Apr; 50(4):746-51. View Abstract
  217. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group. J Clin Oncol. 2008 Feb 20; 26(6):913-8. View Abstract
  218. Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome. Clin Cancer Res. 2007 Jun 01; 13(11):3191-7. View Abstract
  219. Criteria for optimizing prognostic risk groups in pediatric cancer: analysis of data from the Children's Oncology Group. J Clin Oncol. 2007 May 20; 25(15):2070-7. View Abstract
  220. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol. 2007 Feb 10; 25(5):493-500. View Abstract
  221. Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study. Clin Cancer Res. 2006 Oct 01; 12(19):5693-7. View Abstract
  222. Survivin mRNA levels are associated with biology of disease and patient survival in neuroblastoma: a report from the children's oncology group. J Pediatr Hematol Oncol. 2006 Jul; 28(7):412-7. View Abstract
  223. Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma. J Clin Oncol. 2006 Jun 20; 24(18):2879-84. View Abstract
  224. A topotecan-containing induction regimen for treatment of high risk neuroblastoma. J Clin Oncol. 2006 Jun 20; 24(18_suppl):9013. View Abstract
  225. Site of metastases does not influence the clinical outcome of children with metastatic Germ Cell Tumors (GCT). A report from the Childrens Oncology Group (COG). J Clin Oncol. 2006 Jun 20; 24(18_suppl):9002. View Abstract
  226. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res. 2006 Jun 15; 66(12):6050-62. View Abstract
  227. Prognostic factors in children with extragonadal malignant germ cell tumors: a pediatric intergroup study. J Clin Oncol. 2006 Jun 01; 24(16):2544-8. View Abstract
  228. POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with Stages I, IIA, IIIA1 Hodgkin Disease: a report from the Children's Oncology Group. J Pediatr Hematol Oncol. 2006 Jun; 28(6):362-8. View Abstract
  229. International neuroblastoma pathology classification adds independent prognostic information beyond the prognostic contribution of age. Eur J Cancer. 2006 May; 42(8):1113-9. View Abstract
  230. Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. J Clin Oncol. 2006 Apr 01; 24(10):1546-53. View Abstract
  231. APE chemotherapy for children with relapsed Hodgkin disease: a Pediatric Oncology Group trial. Pediatr Blood Cancer. 2006 Mar; 46(3):320-4. View Abstract
  232. Treatment of stage I, IIA, IIIA1 pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: a Pediatric Oncology Group (POG) study. Pediatr Blood Cancer. 2006 Feb; 46(2):198-202. View Abstract
  233. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy. J Clin Oncol. 2005 Dec 01; 23(34):8819-27. View Abstract
  234. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med. 2005 Nov 24; 353(21):2243-53. View Abstract
  235. Epidural compression in neuroblastoma: Diagnostic and therapeutic aspects. Cancer Lett. 2005 Oct 18; 228(1-2):283-99. View Abstract
  236. The role of age in neuroblastoma risk stratification: the German, Italian, and children's oncology group perspectives. Cancer Lett. 2005 Oct 18; 228(1-2):257-66. View Abstract
  237. One- and two-stage designs for stratified phase II clinical trials. Stat Med. 2005 Sep 15; 24(17):2597-611. View Abstract
  238. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol. 2005 Sep 20; 23(27):6459-65. View Abstract
  239. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 2005 Sep 20; 23(27):6466-73. View Abstract
  240. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study. Cancer. 2005 Aug 15; 104(4):841-7. View Abstract
  241. Outcome of high risk (HR) stage 3 neuroblastoma (NB) with myeloablative therapy and 13-cis-retinoic Acid. J Clin Oncol. 2005 Jun; 23(16_suppl):8503. View Abstract
  242. Evidence for an age cut-off greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group (COG). J Clin Oncol. 2005 Jun; 23(16_suppl):8500. View Abstract
  243. Chromosome arm 11q deletion predicts for neuroblastoma outcome: A Children's Oncology Group study. J Clin Oncol. 2005 Jun; 23(16_suppl):6. View Abstract
  244. Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro. Mol Cancer Ther. 2005 Apr; 4(4):547-53. View Abstract
  245. Preradiation chemotherapy with methotrexate, cisplatin, 5-fluorouracil, and leucovorin for pediatric nasopharyngeal carcinoma. Cancer. 2005 Feb 15; 103(4):850-7. View Abstract
  246. Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study. J Clin Oncol. 2004 Oct 15; 22(20):4119-26. View Abstract
  247. Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors: A Pediatric Intergroup Study--Pediatric Oncology Group 9048 and Children's Cancer Group 8891. J Clin Oncol. 2004 Sep 01; 22(17):3563-9. View Abstract
  248. Recurrent neuroblastoma: Randomized treatment with topotecan + cyclophosphamide (T+C) vs. topotecan alone(T). A POG/CCG Intergroup Study. J Clin Oncol. 2004 Jul 15; 22(14_suppl):8512. View Abstract
  249. Antibody-dependent cellular cytotoxicity (ADCC) in COG ANBL0032: A phase III randomized trial of chimeric anti-GD2 and GM-CSF/IL2 in high risk neuroblastoma following myeloablative therapy and autologous stem cell transplant (ASCT). J Clin Oncol. 2004 Jul 15; 22(14_suppl):2582. View Abstract
  250. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882. J Clin Oncol. 2004 Jul 01; 22(13):2691-700. View Abstract
  251. Efficacy of complete resection for high-risk neuroblastoma: a Children's Cancer Group study. J Pediatr Surg. 2004 Jun; 39(6):931-6. View Abstract
  252. Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study. J Pediatr Surg. 2004 Mar; 39(3):424-9; discussion 424-9. View Abstract
  253. The effect of neoadjuvant chemotherapy and surgery in children with malignant germ cell tumors of the genital region: a pediatric intergroup trial. J Pediatr Surg. 2003 Jun; 38(6):910-2. View Abstract
  254. Malignant retroperitoneal and abdominal germ cell tumors: an intergroup study. J Pediatr Surg. 2003 Mar; 38(3):315-8; discussion 315-8. View Abstract
  255. Excellent outcome in patients with stage I germ cell tumors of the testes: a study of the Children's Cancer Group/Pediatric Oncology Group. J Pediatr Surg. 2003 Mar; 38(3):319-24; discussion 319-24. View Abstract
  256. Treatment of unresectable and metastatic hepatoblastoma: a pediatric oncology group phase II study. J Clin Oncol. 2002 Aug 15; 20(16):3438-44. View Abstract
  257. p16/p14(ARF) cell cycle regulatory pathways in primary neuroblastoma: p16 expression is associated with advanced stage disease. Clin Cancer Res. 2001 Nov; 7(11):3481-90. View Abstract
  258. Treatment and outcome of 83 children with intraspinal neuroblastoma: the Pediatric Oncology Group experience. J Clin Oncol. 2001 Feb 15; 19(4):1047-55. View Abstract
  259. Malignant mediastinal germ cell tumors: an intergroup study. J Pediatr Surg. 2001 Jan; 36(1):18-24. View Abstract
  260. Prognostic significance of EPHB6, EFNB2, and EFNB3 expressions in neuroblastoma. Med Pediatr Oncol. 2000 Dec; 35(6):656-8. View Abstract
  261. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J Clin Oncol. 2000 Nov 01; 18(21):3604-13. View Abstract
  262. Implications of EPHB6, EFNB2, and EFNB3 expressions in human neuroblastoma. Proc Natl Acad Sci U S A. 2000 Sep 26; 97(20):10936-41. View Abstract
  263. Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group Study. J Pediatr Hematol Oncol. 2000 May-Jun; 22(3):197-205. View Abstract
  264. High-level expression of EPHB6, EFNB2, and EFNB3 is associated with low tumor stage and high TrkA expression in human neuroblastomas. Clin Cancer Res. 1999 Jun; 5(6):1491-6. View Abstract
  265. A comparison of urethral profilometry using microtip and fiberoptic catheters. Int Urogynecol J Pelvic Floor Dysfunct. 1999; 10(6):371-4. View Abstract
  266. Immediate reproducibility of upper limit of vulnerability measurements in patients undergoing transvenous implantable cardioverter defibrillator implantation. J Cardiovasc Electrophysiol. 1998 Jun; 9(6):588-95. View Abstract
  267. Atypical squamous cells of undetermined significance: a comparative review of original and automated rescreen diagnosis of cervicovaginal smears with long term follow-up. Cancer. 1997 Dec 25; 81(6):348-53. View Abstract
  268. Analysis of homeopathic treatment of childhood diarrhea. Pediatrics. 1995 Nov; 96(5 Pt 1):961-4. View Abstract
  269. Circadian pattern of ventricular tachyarrhythmias in patients with implantable cardioverter-defibrillators. J Am Coll Cardiol. 1995 Mar 15; 25(4):901-7. View Abstract
  270. ELISA for antibody to hepatitis E virus (HEV) based on complete open-reading frame-2 protein expressed in insect cells: identification of HEV infection in primates. J Infect Dis. 1993 Aug; 168(2):369-78. View Abstract
  271. Amphotropic murine leukemia retrovirus is not an acute pathogen for primates. Hum Gene Ther. 1990; 1(1):15-30. View Abstract
  272. Oculopharyngeal muscular dystrophy. N Engl J Med. 1963 Jan 17; 268:163. View Abstract

Contact Wendy London

Phone: 617-632-4895
Print Profile